Clinical trial
Thalidomide-Dexamethasone for Multiple Myeloma
NCT00038090 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038090 |
|---|---|
| Title | Thalidomide-Dexamethasone for Multiple Myeloma |
| Official title | Thalidomide-Dexamethasone for Multiple Myeloma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Thalidomide, Dexamethasone |
| Enrollment | 83 |
| Start date | Jun 1, 2000 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | May 29, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: